Phase 2 N=38 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Lambert-Eaton Myasthenic Syndrome · Eaton-Lambert Myasthenic Syndrome
Primary: Number of Participants With 30% or More Deterioration in Triple Timed Up & Go (3TUG) Test, Compared to Time-matched Baseline — 0; 13 Participants — p=<0.0001
Phase 2 N=35 Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Number of Patients With Dose Limiting Toxicity — 0; 4; 2; 2 Participants — p=0.03
Phase 2 N=63 Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Recommended Phase II Dose (RPTD) for the Capecitabine and Aflibercept Doublet Combination — 850 mg/m2
Phase 2 N=45 Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Leukemia
Primary: Percentage of Patients Achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) on Single Agent CC-5013 at 6 Months — 68.9 percentage of…
Phase 2 N=630 Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Influenza
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs — 40; 50 percentage of participants analyzed — p=0.046
Phase 2 N=22 An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
Atopic Dermatitis
Primary: Incidence of Skin Irritation — 0 Participants
Phase 2 N=28 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
Gambling · Tobacco Use Disorder
Primary: Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score — 23.5; 20.4 units on a scale
Phase 2 N=155 Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
Staphylococcal Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) During Days 1-7 — 2; 1; 17; 4 participants
Phase 2 N=3 Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
Central Nervous System Metastases · Leptomeningeal Metastases · Recurrent Breast Cancer
Primary: Survival Free of Neurological Progression, Measured in Weeks — 6 weeks
Phase 2 N=27 Prescription Opioid Effects in Abusers Versus Non-Abusers
Opioid-Related Disorders · Substance-Related Disorders
Primary: Breakpoint — 25; 400; 1400; 850 Mouse Clicks
Phase 2 N=25 A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics
Diabetes Mellitus Type 1
Primary: Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements — -2.09; 2.83; -1.92; -1.10 mg/dL
Phase 2 N=15 Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Mucopolysaccharidosis IVA · Morquio A Syndrome · MPS IVA
Primary: To Evaluate Safety and Tolerability of Infusions of BMN 110 at a Dose of 2.0 mg/kg/Week Over a 52-week Period in MPS IVA Subjects Less Than 5 Years of Age at Time of…
Phase 2 N=55 Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
Gastric Adenocarcinoma · Stage II Gastric Cancer · Stage III Gastric Cancer
Primary: Histological Response Determined by FDG Uptake Correlates — 2; 3; 38 participants
Phase 2 N=172 Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Head and Neck Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants — 16.4 Percentage of participants — p=<0.001